RE:Oncolytics Biotech product From your mouth to the BOD's ears. You're right about the fact that BP shouldn't sit on their hands, and the more indications that are proven to benefit from Pela, the more the acquisition price escalates. I'm of the opinion that PFE, having access to real-time data, knew months and months ago that they would B/O Onc for mBC alone. Well guess what happened...they didn't move...pancreatic data blew the scientific world away, and the purchase price doubled in a few short months. My opinion, $2-4b jumped to $4-$8b or more. Good luck.